CAJ | 학술논문

目的：分析术前血清癌胚抗原(carcinoembryonic antigen,CEA)质量浓度对非小细胞肺癌(non-small cell lung cancer, NSCLC)的预后价值。方法检索截至2014年6月1日数据库相关研究文献,针对术前血清 CEA 质量浓度与 NSCLC 患者生存关系进行定量评估并符合条件的文献行 meta 分析,汇总生存数据并行定量分析。结果共有16个研究(n =4296)评估 NSCLC患者中术前 CEA 质量浓度与患者的生存。组合风险比(hazard ratio,HR)提示 NSCLC 患者中,术前血清 CEA 过表达与总生存期不良预后相关(HR=2.28,95% CI：2.2~2.31)。同时对于病理分期为Ⅰ期的 NSCLC 患者,风险比是1.98(95% CI：1.73~2.15)。患者资料进行分层分析后结果显示亚洲和非亚洲患者中显著风险相关。然而,在所有研究中发现存在显著的异质性。结论术前血清 CEA 的高表达提示 NSCLC 患者预后不良。
목적：분석술전혈청암배항원(carcinoembryonic antigen,CEA)질량농도대비소세포폐암(non-small cell lung cancer, NSCLC)적예후개치。방법검색절지2014년6월1일수거고상관연구문헌,침대술전혈청 CEA 질량농도여 NSCLC 환자생존관계진행정량평고병부합조건적문헌행 meta 분석,회총생존수거병행정량분석。결과공유16개연구(n =4296)평고 NSCLC환자중술전 CEA 질량농도여환자적생존。조합풍험비(hazard ratio,HR)제시 NSCLC 환자중,술전혈청 CEA 과표체여총생존기불량예후상관(HR=2.28,95% CI：2.2~2.31)。동시대우병리분기위Ⅰ기적 NSCLC 환자,풍험비시1.98(95% CI：1.73~2.15)。환자자료진행분층분석후결과현시아주화비아주환자중현저풍험상관。연이,재소유연구중발현존재현저적이질성。결론술전혈청 CEA 적고표체제시 NSCLC 환자예후불량。
Objective To explore the prognostic role of preoperative serum carcinoembryonic antigen(CEA) levels in non-small cell lung cancer(NSCLC) patients. Methods Electronic databases updated to June 1, 2014 were searched to find relevant studies. A meta-analysis was made with eligible studies which quantitatively evaluated the relationship between preoperative serum CEA level and survival of patients with NSCLC. Survival data were aggregated and quantitatively analyzed. Results Totally 16 studies(n=4 296 patients) were enrolled. We evaluated the correlation between preoperative serum CEA level and survival in patients with NSCLC. Combined hazard ratios suggested that preoperative serum CEA overexpression was associated with poor prognosis of overall survival(OS)(HR=2. 28, 95%CI: 2. 24-2. 31) in patients. Meanwhile, for p-stage I NSCLC, the HR(95% CI) was 1. 98(1. 73-2. 15). In the stratified analysis by patient source, significant risks were found among Asians and non-Asians. However, significant heterogeneity was observed among all studies. Conclusion In the present meta-analysis, preoperative serum CEA overexpression indicated a poor prognosis for patients with NSCLC.